These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30801313)

  • 1. New Warning for the Multiple Sclerosis Drug Alemtuzumab.
    Aschenbrenner DS
    Am J Nurs; 2019 Mar; 119(3):21. PubMed ID: 30801313
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune-Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis.
    Bolte FJ; Schmidt HH; Schlevogt B
    Hepatology; 2021 Jan; 73(1):460-463. PubMed ID: 32583445
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    Gao J; Jones J; Damato EM; Coles A
    J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
    Gaitán MI; Ysrraelit MC; Correale J
    JAMA Neurol; 2017 Sep; 74(9):1143-1144. PubMed ID: 28715536
    [No Abstract]   [Full Text] [Related]  

  • 5. Autoimmune storm following alemtuzumab.
    Chan C; Beauchemin P; Sayao AL; Carruthers M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Barton J; Hardy TA; Riminton S; Reddel SW; Barnett Y; Coles A; Barnett MH
    Neurology; 2017 Mar; 88(10):1004-1006. PubMed ID: 28179462
    [No Abstract]   [Full Text] [Related]  

  • 7. Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity.
    Bianco A; Nicoletti T; Traini E; Del Giacomo P; Del Gatto V; Lucchini M; Rota CA; Mirabella M
    J Endocrinol Invest; 2020 Aug; 43(8):1159-1161. PubMed ID: 32130689
    [No Abstract]   [Full Text] [Related]  

  • 8. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab-associated diffuse alveolar damage - a case report.
    Bayas A; Menacher M; Schwaiblmair M; Märkl B; Naumann M
    BMC Neurol; 2020 Sep; 20(1):357. PubMed ID: 32967641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
    Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
    Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
    Aitken L; Patel R; D'Rozario J; Choi P
    Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab to be restricted pending review, says EMA.
    McCall B
    Lancet; 2019 Apr; 393(10182):1683. PubMed ID: 31034363
    [No Abstract]   [Full Text] [Related]  

  • 13. Glomerulonephritis With Positive Anti-Glomerular Basement Membrane Antibodies Following Alemtuzumab Treatment.
    White E; Watson A; Holian J; McGuigan C; O'Riordan S
    Ir Med J; 2020 Mar; 113(3):41. PubMed ID: 32815683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
    Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
    Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient.
    Baroncini D; Annovazzi P; Guaschino C; Minonzio G; Hametner S; Stadelmann C; Comi G; Ghezzi A; Zaffaroni M
    Mult Scler Relat Disord; 2020 Jun; 41():102061. PubMed ID: 32203930
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
    Alamo A; Condorelli RA; La Vignera S; Calogero AE
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
    Russo CV; Saccà F; Paternoster M; Buonomo AR; Gentile I; Scotto R; Brescia Morra V; Mansueto G
    Mult Scler; 2020 Jan; 26(1):123-126. PubMed ID: 30882274
    [No Abstract]   [Full Text] [Related]  

  • 18. Spontaneous multiple cervical artery dissections after alemtuzumab.
    Durand-Dubief F; Marignier R; Berthezene Y; Cottin J; Nighoghossian N; Vukusic S
    Mult Scler; 2020 Mar; 26(3):381-383. PubMed ID: 31070502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
    Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
    Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Ahrabian D; Neill L; Bell R; Leary SM
    Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.